CDEK
← All drugs Report issue

risankizumab

Trade name: Skyrizi

mAbapproved

Approved

Apr 23, 2019

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection. — Wikipedia

Clinical trial activity

82 trials · 19 clinical orgs · 1 marketing orgs

Phase 1
22
Phase 2
52
Phase 3
34
Phase 4
7

Earliest trial started Apr 1, 2012 (NCT01577550)

Timeline

2010s

  1. Jan 1, 2012

    AbbVie — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    AbbVie — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2016

    AbbVie — Earliest Phase 3 Sponsor(trial)

  4. Apr 23, 2019

    AbbVie — Earliest FDA Approval

  5. Apr 23, 2019

    AbbVie — Marketing Organization

  6. Apr 23, 2019

    AbbVie — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedApr 23, 2019

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • abbv-066
  • bi 655066
  • risankizumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07258641Phase 1/Phase 2 (Phase 2)Jan 15, 2026University of Groningen
NCT07177118Phase 3Oct 20, 2025Wenzhou Medical University
NCT07138898Phase 2Sep 30, 2025New York University
NCT07071519Phase 3Jul 28, 2025AbbVie
NCT06865105Phase 2Jun 30, 2025AbbVie
NCT06880744Phase 3Jun 17, 2025AbbVie
NCT07007091Phase 1Jun 12, 2025AbbVie
NCT06946524Phase 1May 8, 2025AbbVie
NCT06937619Phase 1Apr 21, 2025AbbVie
NCT06606808Phase 1/Phase 2 (Phase 2)Oct 31, 2024University of Groningen
NCT06624228Phase 3Oct 31, 2024UCB
NCT06641089Phase 3Oct 15, 2024MoonLake Immunotherapeutics AG
NCT06632938Phase 1Oct 8, 2024AbbVie
NCT06571266Phase 1Sep 11, 2024AbbVie
NCT06548542Phase 2Sep 4, 2024AbbVie
NCT06487572Phase 1Jul 23, 2024AbbVie
NCT06333860Phase 4May 10, 2024AbbVie
NCT06346288Phase 4Apr 24, 2024AbbVie
NCT06298188N/AMar 31, 2024Hebrew University
NCT06100744Phase 3Jan 16, 2024AbbVie
Showing 20 of 82 trials
Page 1 / 5

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AbbVieFor profit696752012
Boehringer IngelheimFor profit15132012
University of GroningenAcademic/Hospital2212024
Ghent UniversityAcademic/Hospital1012020
Hebrew UniversityAcademic/Hospital1112024
Istituto Clinico Humanitas - Rozzano (MI), ItalyAcademic/Hospital1112021
Janssen Pharmaceutica NVFor profit1112021
Katholieke Universiteit LeuvenAcademic/Hospital1012020
MoonLake Immunotherapeutics AGFor profit1112024
National Institute of Allergy and Infectious Diseases (NIAID)Government1112020
New York UniversityAcademic/Hospital1112025
Oregon Medical Research CenterFor profit1112022
Radboud UniversityAcademic/Hospital1112020
Robarts Clinical TrialsFor profit1012023
Rockefeller UniversityAcademic/Hospital1112021
UCBFor profit1112024
University of CalgaryAcademic/Hospital1112023
Wenzhou Medical UniversityAcademic/Hospital1112025
ZonMw: The Netherlands Organisation for Health Research and DevelopmentAcademic/Hospital1012020
19 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
AbbVieFor profitMKTGApr 23, 2019
AbbVieFor profitNDAApr 23, 2019